CsA+Rapamune+CS + CsA+MMF+CS
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Inflammation
Conditions
Inflammation
Trial Timeline
Apr 1, 2006 → Mar 1, 2008
NCT ID
NCT01601821About CsA+Rapamune+CS + CsA+MMF+CS
CsA+Rapamune+CS + CsA+MMF+CS is a approved stage product being developed by Pfizer for Inflammation. The current trial status is completed. This product is registered under clinical trial identifier NCT01601821. Target conditions include Inflammation.
What happened to similar drugs?
1 of 14 similar drugs in Inflammation were approved
Approved (1) Terminated (2) Active (11)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01601821 | Approved | Completed |
Competing Products
20 competing products in Inflammation